Carisma Therapeutics (CARM)
OTHER OTC:CARM
Top Page
Carisma Therapeutics
(OTC:CARM)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.04
▼(-10.00% Downside)
Action:ReiteratedDate:01/13/26
The score is driven primarily by very weak financial performance (persistent losses, heavy cash burn, and negative equity) and materially negative corporate events (Nasdaq delisting and wind-down). Technicals also reflect a sustained downtrend, while valuation looks optically low but is not supportive given the financial and operational pressures.
Positive Factors
High Gross Profit Margin
A high gross profit margin indicates effective cost management in production, which can support future profitability if revenue growth is achieved.
Negative Factors
Negative Cash Flow
Persistent negative cash flow can strain liquidity, limiting the company's ability to invest in growth and sustain operations long-term.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Profit Margin
A high gross profit margin indicates effective cost management in production, which can support future profitability if revenue growth is achieved.
Read all positive factors
Carisma Therapeutics (CARM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.42M
Dividend YieldN/A
Average Volume (3M)2.25M
Price to Earnings (P/E)<0.1
Beta (1Y)1.97
Revenue Growth159.68%
EPS GrowthN/A
CountryUS
Employees46
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,845,078
10 Day Avg. Volume3,913,183
30 Day Avg. Volume2,245,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.62
Price to Sales (P/S)0.88
P/FCF Ratio-0.29
Enterprise Value/Market Cap-0.42
Enterprise Value/Revenue-0.01
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda-0.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Carisma Therapeutics Business Overview & Revenue Model
Company Description
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technol...
How the Company Makes Money
Carisma Therapeutics generates revenue primarily through a combination of research and development funding, partnerships, and potential future product sales. The company may enter into collaborations with larger pharmaceutical firms that provide u...
Carisma Therapeutics Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
28
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.63M | 19.63M | 14.92M | 9.83M | 26.54M | 11.24M |
| Gross Profit | 51.61M | -40.04M | -59.21M | 9.83M | 26.46M | 11.24M |
| EBITDA | 13.66M | -56.83M | -85.89M | -56.19M | -8.52M | -27.93M |
| Net Income | 8.04M | -60.48M | -86.88M | -61.23M | -336.00K | -28.35M |
Balance Sheet | ||||||
| Total Assets | 6.55M | 30.46M | 89.55M | 72.15M | 312.60M | 188.45M |
| Cash, Cash Equivalents and Short-Term Investments | 2.78M | 18.83M | 77.61M | 52.00M | 162.64M | 55.39M |
| Total Debt | 762.00K | 2.48M | 3.12M | 40.16M | 0.00 | 0.00 |
| Total Liabilities | 7.42M | 58.37M | 63.02M | 214.82M | 140.89M | 197.68M |
| Stockholders Equity | -867.00K | -27.91M | 26.53M | -157.06M | 171.71M | -9.23M |
Cash Flow | ||||||
| Free Cash Flow | -22.41M | -60.04M | -82.31M | -12.23M | -39.20M | -27.45M |
| Operating Cash Flow | -22.41M | -59.92M | -81.18M | -7.57M | -37.33M | -27.01M |
| Investing Cash Flow | 687.00K | -123.00K | 72.41M | -32.56M | -1.87M | -440.00K |
| Financing Cash Flow | -2.38M | 344.00K | 62.18M | 35.77M | 15.96M | 72.26M |
Carisma Therapeutics Technical Analysis
Negative
0.04
Price Trends
0.04
Negative
0.04
Negative
0.16
Negative
Market Momentum
>-0.01
Positive
36.00
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CARM, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and below the 200-day MA of 0.16, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 36.00 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CARM.
Carisma Therapeutics Risk Analysis
Carisma Therapeutics disclosed 82 risk factors in its most recent earnings report. Carisma Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Carisma Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $9.47M | -0.31 | -97.58% | ― | -46.88% | 34.83% | |
46 Neutral | $44.74M | -0.64 | -80.00% | ― | ― | 9.63% | |
41 Neutral | $4.81M | ― | 212.59% | ― | -41.05% | 57.35% | |
41 Neutral | $14.04M | -0.15 | -356.99% | ― | ― | 54.62% | |
40 Underperform | $1.42M | 0.06 | -28.86% | ― | 159.68% | ― |
* Healthcare Sector Average
CARM
Carisma Therapeutics
0.03
-0.16
-82.90%
AIM
AIM ImmunoTech
0.59
-3.44
-85.34%
GTBP
GT Biopharma
0.45
-1.81
-80.31%
SNSE
Sensei Biotherapeutics
33.38
27.38
456.33%
BOLT
Bolt Biotherapeutics
4.93
-2.10
-29.87%
CERO
CERo Therapeutics Holdings
0.03
-14.17
-99.77%
Carisma Therapeutics Corporate Events
Executive/Board ChangesDelistings and Listing Changes
Carisma Therapeutics Announces Nasdaq Delisting and Leadership Changes
Negative
Dec 5, 2025
Carisma Therapeutics Inc. announced the voluntary delisting of its common stock from Nasdaq, effective December 10, 2025, following a suspension due to noncompliance with Nasdaq Listing Rules. The company plans to terminate its reporting obligatio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.